c v i . s ta n fo rd .e d u | 1

Welcome New Faculty! Dr. Jeffrey Teuteberg joins the Depart-ment of Medicine - Division of Cardiovascular Medicine and the Cardiovascular Institute as the Sec-tion Chief of Heart Failure, Cardiac Transplant and Mechanical Circulatory Support. He arrives at Stanford from the University of Pittsburgh Medical Center where he developed his clinical research career in outcomes and risk factors in patients who have mechanical circulatory support and novel immunosuppression in patients who receive cardiac transplantation. In addition to his administra-tive responsibilities he will continue to be clinically active, caring for patients with advanced heart failure as well as those who have received cardiac transplantation and mechanical support. He will also focus on building the clinical research program in the Heart Failure Section. Dr. Teuteberg also remains active in medical societies and will be serving as the President of the International Society for Heart and Lung Transplantation in 2018.

SUMMER 2017

Faculty Recruitment The Cardiovascular Institute and the Department of Medicine at Stanford Universityare recruiting a full-time academic faculty with expertise in any of the areas of drug/gene delivery, polymer chemistry/nanotechnology, bioengineering/biomaterial sciences, biomedical formulation, clinical medicinal chemistry, medical pharmacology/molecular pharma-cology, toxicology, bioinformatics, applied proteomics and pharmacogenomics at the rank of Assistant or Associate Professor in the Non-Tenured Line-Research (NTL-R). More details.

Lucile Packard Children’s Hospital Stanford ranks among the nation’s best in pediatric specialty care in U.S. News In the U.S. News & World Report’s 2017–2018 Best Children’s Hos-pitals survey, Lucile Packard Children’s Hospital Stanford once again achieved rankings in all ten pediatric specialties.

“As we approach the debut of our newly expanded hospital this year, these rankings affirm the quality of specialty care that we are so proud to provide our patients,” said Christopher G. Dawes, Packard Children’s president and chief executive officer. “That quality will be amplified in our new, state-o f-the-art facility when it opens in December.”

The new main building adds 149 patient beds, nearly all of them private, which Dawes says will serve to improve safety and quality as well as the patient experience. The expanded campus includes 3.5 acres of green space and gardens and will more than double the size of the current hospital. It will also allow for the original building to undergo enhancement renovations.

Read more: http://www.stanfordchildrens.org/en/about/news/releas-es/2017/us-news-world-reports-2017-2018-best-childrens-hospitals

Stanford Hospital ranks among top 10 in the country STANFORD, CALIF. – Stanford Hospital was named top 10 on the U.S. News & World Report’s Honor Roll of the best hospitals in the nation. The ranking, which reflects the hospital’s spot among the top 1 percent of more than 5,000 hospitals surveyed, is based on outstanding performance across multiple areas of care, with factors such as quality, patient safety, and reputation. Stanford Hospital was also ranked in 13 medical specialties and the number one hos-pital in the San Jose metropolitan area.

“We are very pleased that Stanford Hospital has again been named to the U.S. News & World Report Honor Roll,” said Stanford Health Care President and CEO David Entwistle. “This national recogni-tion is a testament to the outstanding commitment to quality pa-tient care and the unique Stanford spirit of innovation shared by all our physicians, nurses, administrative staff, and everyone on our care teams. We look forward to continuing our collective work to ensure that each and every patient receives personalized care of the highest quality and value.”

Read more: https://stanfordhealthcare.org/newsroom/articles/2017/stanford-named-us-news-honor-roll-2017-18.html

| 2

Victor J. Dzau, MD President, National Academy of MedicineJames B. Duke Professor of MedicineDuke University School of Medicine

Rui-Ping Xiao, MD, PhD Professor at the Institute of Molecular Medicine Peking University

Joseph C. Wu, MD, PhD Director, Stanford Cardiovascular Institute Simon H. Stertzer Professor of Medicine and Radiology

David Entwistle, MHSA President and Chief Executive OfficerStanford Health Care

Lloyd B. Minor, MD Carl and Elizabeth Naumann Professor for the Dean of the School of Medicine; Professor of Otolaryngology, Head and Neck Surgery, and by courtesy, of Neurobiology and Bioengineering

Christopher G. Dawes, MBA President and Chief Executive Officer Lucile Packard Children’s Hospital

Zhe Zheng, MD, PhD Vice President, Fuwai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences; Professor, Deputy Director, National Center for Cardiovascular Diseases

Brian Kobilka, MD2012 Nobel Laureate Helene Irwin Fagan Chair in Cardiology Professor, by courtesy, of Chemical and Systems Biology Stanford University

Each year, CVI partners with leading institutions around the world to share research and foster collaboration of researchers, clinicians and trainees. This year, pioneering researchers from the twelve leading cardiovascular hospitals in China and U.S. will convene to discuss the latest advances in cardiovascular research.

Stanford-China Cardiovascular Research SymposiumSeptember 21-22, 2017 Li Ka Shing Center, Stanford University

WELCOME REMARKS

KEYNOTES

PARTICIPATING INSTITUTIONS

ORGANIZING COMMITTEEJoseph C. Wu, MD, PhD

Director, Stanford Cardiovascular Institute

Simon H. Stertzer Professor of Medicine and Radiology

Alan Yeung, MD

The Li Ka Shing Professor in Cardiology; Co-Chief,

(Clinical), Division of Cardiovascular Medicine,

Stanford School of Medicine

Hana Lee, MPH

Associate Director, Stanford Cardiovascular Institute

c v i . s t a n f o r d . e d u

Li Wang, MD, PhD

Professor, State Key Laboratory of Cardiovascular

Disease, Fuwai Hospital, Peking Union Medical College

and Chinese Academy of Medical Sciences

Feng Lan, PhD

Professor and Deputy Director, Beijing Lab for Cardio-

vascular Precision Medicine, Beijing Institute of Heart

Lung and Blood Vessel Disease, Beijing Anzhen Hospi-

tal, Capital Medical University

Sponsored in part by:

包玉 星 基

金

CHI-L

I PAO FOUNDATIO

N

Register & Submit Posters http:tinyurl.com/schina2017

c v i . s ta n fo rd .e d u | 3

2017 Silicon Valley’s Heart Ball raised over $825,000 to fund critical research and programs in the Silicon Valley The 2017 Heart Ball was held on June 3, 2017 hosted by the American Heart Association & American Stroke Association. The gala brought together physicians, philanthropists and local business communities, including prominent leaders in the technology and finance industry.

The Institute currently consists of over 241 faculty members representing physicians,

surgeons, engineers, basic and clinical researchers. The mission of the Institute is integrat-

ing fundamental research across disciplines and applying technology to prevent and treat

cardiovascular disease.

To support cardiovascular research and education at CVI, please contact: Cathy Hutton,

Senior Associate Director, Medical Center Development at cathy.sutton@stanford.edu or

Hana Lee, Associate Director, Cardiovascular Institute at hanalee@stanford.edu.

About the Stanford Cardiovascular Institute

Cathy Hutton, MBA

For more information: http://med.stanford.edu/cvi/support-our-research.html and http://cvi.stanford.edu.

Hana Lee, MPH

c v i . s ta n fo rd .e d u | 4

Stanford researchers find intriguing clues about obesity by counting steps via smartphones By Tom Abate

Scientists tie heart patients’ increased shingles risk to glucose-gobbling immune cells By Bruce Goldman

People with coronary artery disease face an elevated risk for shingles because aberrant immune cells dial down the body’s immune response to viral pathogens, Stanford research shows. In a study published online June 12 in the Journal of Clinical Investigation, the researchers learned that a set of immune cells whose aberrantly large appetite for glucose predisposes people to this heart condition also disables the immune response to viral infections — and does so using the same immune-response-derailing technique often employed by cancer cells.

Read more: http://med.stanford.edu/news/all-news/2017/06/heart-patients-increased-shingles-risk-tied-to-immune-cells.html

For full paper: Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. Ryu Watanabe, Tsuyoshi Shirai, Hong

Namkoong, Hui Zhang, Gerald J. Berry, Barbara B. Wallis, Benedikt Schaefgen, David G. Harrison, Jennifer A. Tremmel, John C. Giaco-

mini, Jörg J. Goronzy, Cornelia M. Weyand. J Clin Invest. 2017;127(7):2725-2738.

Using step data captured by smartphones, Stanford researchers have defined a new public health risk they call activity inequality. This oc-curs when large gaps develop inside a country between people who walk a lot and those who walk very little, leading to unhealthy levels of obesity. (Image credit: Tim Althoff )

A global study based on daily steps counted by smartphones dis-covers “activity inequality.” It’s similar to income inequality, except that the “step-poor” are prone to obesity while the “step-rich” tend toward fitness and health.

Stanford researchers using smartphones to track the activity lev-els of hundreds of thousands of people around the globe made an intriguing discovery: In countries with little obesity, people mostly walked a similar amount per day. But big gaps between people who walked a lot and those who walked very little coincided with much higher levels of obesity.

The ground-breaking study, appearing in Nature, used data cap-tured from smartphones to analyze the habits of 717,000 men and women from 111 countries, whose steps were studied for an aver-age of 95 days.

The researchers, led by computer scientist Jure Leskovec, PhD and bioengineer Scott Delp, PhD dubbed this phenomenon “ac-tivity inequality” to evoke the well-established concept of income inequality. “If you think about some people in a country as ‘activity rich’ and others as ‘activity poor,’ the size of the gap between them is a strong indicator of obesity levels in that society,” Delp said.

A related finding was the powerful role that gender played in coun-try-to-country differences. Prior studies of physical activity, done mainly in the United States, have shown that men walk more than women, and this was borne out in the global findings. What sur-prised researchers, however, was how greatly this gender step gap varied from country to country with negative consequences for

women.” When activity inequality is greatest, women’s activity is reduced much more dramatically than men’s activity, and thus the negative connections to obesity can affect women more greatly,” Leskovec said.

The researchers, who are sharing their findings on an activity in-equality website, hope their work will help improve public health campaigns against obesity and support policies to make cities more “walkable.”

Using step data captured by smartphones, Stanford researchers have defined a new public health risk they call activity inequal-ity. This occurs when large gaps develop inside a country between people who walk a lot and those who walk very little, leading to unhealthy levels of obesity.

Read more: http://news.stanford.edu/2017/07/10/stanford-researchers-find-intriguing-clues-obesity-counting-steps-via-smartphones/ & http://www.cnn.com/2017/07/14/health/why-countries-are-obese-culture-exercise-diet/index.html

Cornelia M. Weyand, MD, PhD

c v i . s ta n fo rd .e d u | 5

Researchers help develop technique for assessing, reducing risk of future stroke By Jennie Dusheck

Using health records, Stanford researchers developed an algorithm for scoring the risk of a stroke patient experiencing a heart condition known as atrial fibrillation, a major risk factor for a second stroke.

One stroke is dangerous, and a second, even more so. One important risk factor for that perilous second stroke is an irregular heart rhythm called atrial fibrillation. If doctors could identify the stroke patients who are most likely to experience atrial fibrillation, they could start treatments that would help prevent a second stroke. But which stroke patients are at risk for the condition has been hard to predict without costly 24/7 monitoring for the hundreds of thou-sands of people who have a first stroke every year.

Now, a team led by researchers at the Stanford University School of Medicine and Santa Clara Valley Medical Center has used electronic medical records to predict the likelihood of a person experiencing atrial fibrillation after either of two kinds of strokes: a cryptogenic stroke or a transient ischemic attack.

A paper describing their findings was published online June 28 in Cardiology. The senior authors are Nigam Shah, MBBS, PhD, associate professor of Biomedical Data Science at Stanford, and Susan Zhao, MD, of Valley Medical Center. Stanford graduate student Albee Ling and Valley Medical Center internist Calvin Kwong, MD, share lead authorship.

“The scoring system we developed is simple to use and the results could help physicians tailor treatment to individual patients,” said Ling. The risk factors — age, obesity, congestive heart failure, hypertension, coronary artery disease, peripheral vascular disease and disease of the heart valves — are the basis of a scoring system that assigns patients to one of three risk groups.

It can help physicians decide which patients to monitor. Once it’s known that patients have a high risk of atrial fibrillation, they can wear a heart monitor at home to see if they actually are experiencing bouts of atrial fibrillation and then, if they are, treated with the appropriate drugs to try to prevent a second stroke.

The study is an example of Stanford Medicine’s focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.

Read more: http://med.stanford.edu/news/all-news/2017/06/researchers-develop-technique-for-assessing-risk-of-future-stroke.html

Stanford Medicine publishes its inaugural 2017 Health Trends Report – Harnessing the Power of Data in HealthHarnessing the power of this data is among the most important tasks facing the medical community, and it’s why the inaugural Stanford Medicine Health Trends Report puts big data at the center of health care’s future. A comprehensive review of research and in-sights from both within and outside of Stanford, the Health Trends Report outlines how more needs to be done to channel the full potential of this new data-driven reality.

Read the full report: http://med.stanford.edu/content/dam/sm/sm-news/documents/StanfordMed-icineHealthTrendsWhitePaper2017.pdf

Nigam Shah, MBBS, PhD

c v i . s ta n fo rd .e d u | 6

Study finds first possible drug treatment for lymphedema By Tracie White

Collaboration between two Stanford labs has resulted in the discovery of a molecular cause for lymphedema and the first possible drug treatment for it.

Tracey Campbell has lived for seven years with lymphedema, a chronic condition that causes un-sightly swelling in her left leg.

When assistant professor Joshua Knowles, MD, PhD (cardiovascular medicine), identifies a patient with familial hypercholesterolemia, that discovery marks the beginning of a hunt. Even as the new patient undergoes treatment to reduce levels of low-density lipoprotein cho-lesterol (LDL-C) and stave off early atheroscle-

rotic cardiovascular disease, a search gets underway for family members who might unknowingly be harboring the same disorder. First in this family-based cascade screening are the proband’s clos-est relatives – parents, siblings, children – followed by screening of the closest relatives of any in that group who are positively identi-fied and then by screening of the closest relatives of any in that group who have the disease.

Familial hypercholesterolemia (FH) is an autosomal dominant ge-netic disease that occurs in approximately 1 in 250 persons. Those

who have FH exhibit very high levels of LDL-C even as children and have a very high (2.5 to 10 times increased) risk of cardiovascular disease. The existence of new therapies that promise to control LDL-C and reduce its attendant risks by about 80 percent increases the urgency to identify patients who are unaware that they have FH.

In a recent publication in the Journal of the American Medical Asso-

ciation (2017;318:381-2), Knowles and his colleagues describe how they trace the disease throughout a family once they have identi-fied a case. Finding new patients in a family requires cholesterol testing or genetic testing or both.

Electronic health records (EHR) are another means of identifying FH patients by searching for a specific ICD-10 code and a family his-tory of FH. Researchers anticipate that they will soon be able to apply algorithms to EHR, laboratory, and billing code data or large-scale DNA sequencing to identify patients as well.

The disease, which stems from a damaged lymphatic system, can lead to infections, disfigure-

Stanley Rockson, MD Mark Nicolls, MD ment, debilitating pain and disability. There is no cure. The only available treatment is to wear

compression garments or use massage to suppress the swelling, which can occur throughout the body in some cases. Campbell — who had two quarts of excess water in her left leg by the time she was diagnosed — has for years worn restrictive garments 24 hours a day and has spent an hour each night massaging the lymph fluid out of her leg.

Lymphedema is uncomfortable, exhausting and dangerous if left uncontrolled. As many as 10 million Americans and hundreds of millions of people worldwide suffer f rom t he condition, m any f rom t he a fter-effects of cancer the rapy treatments. Now the re’s new hop e for a p os sible pharmaceutical treatment for patients like Campbell. A study led by scientists at the Stanford University School of Medicine has uncovered for the first time the molecular mechanism responsible for triggering lymphedema, as well as a drug with the potential for inhibiting that process.

The study was published May 10 in Science Translational Medicine.

“We figured out that the biology behind what has been historically deemed the irreversible process of lymphedema is, in fact, reversible if you can turn the molecular machinery around,” said Stanley Rockson, MD, professor of cardiovascular medicine and the Allan and Tina Neill Professor of Lymphatic Research and Medicine at Stanford. Rockson shares senior authorship of the study with Mark Nicolls, MD, professor of pulmonary and critical care medicine. Stanford research scientists Wen “Amy” Tian, PhD, and Xinguo Jiang, MD, PhD, share lead authorship of the study and are also affiliated with the Veterans Affairs Palo Alto Health Care System.

Read more: http://med.stanford.edu/news/all-news/2017/05/study-finds-first-possible-drug-treatment-for-lymphedema.html

Cascade screening for familial hypercholester-olemia and the use of genetic testing

Read full article: Knowles JW, Rader DJ, Khoury MJ. Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing. JAMA. 2017;318(4):381–382.

c v i . s ta n fo rd .e d u | 7

AHA awards $2 million for cardiovascular disease research By American Heart Association News

New studies will soon get underway thanks to a pair of million-dol-lar research grants announced Friday by the American Heart Asso-ciation. One project will look at how to match the right drug to the right patient, and the other will attempt to extend the effectiveness of high blood pressure drugs for certain patients.

The two Merit Awards, each for $1 million doled out over five years, went to Joseph Wu, MD, PhD, from Stanford University School of Medicine and Garret FitzGerald, MD, from the University

of Pennsylvania.

Ivor Benjamin, M.D., chairs the AHA’s research committee and said the goal is to support “visionary leaders.”

Wu plans to use information from stem cells to speed up the slow, expensive process of bringing a new drug to market — which can take years and cost millions, sometimes billions. Such a step would also help doctors who “are making educated but still semi-blind guesses” about a drug’s effectiveness for a particular patient, according to Wu.

“Our project has tremendous potential significance for testing new drugs very efficiently compared to the traditional drug screening that the pharmaceutical industry has to go through — a process that has stagnated and become almost too costly to help patients,” said Wu, director of the Stanford Cardiovascular Institute. Using so-called induced stem cells and novel techniques to grab genetic information, Wu’s team hopes to launch precision cardiovascular medicine from bench to bedside by matching “the best drugs for the individuals who will be most likely to benefit from them, as well as reduce mistakes in giving the wrong drugs to patients,” he said.

The AHA’s Merit Awards fund novel approaches to major research challenges in cardiovascular disease that have the potential to pro-duce an unusually high impact. Last year, the AHA funded research studying how heart cells regenerate and another project examining what triggers coronary heart disease.

Read more: http://news.heart.org/aha-awards-2-million-for-cardiovascular-disease-research/

Notable Faculty Awards AHA recently announced the 2017 achievement awards which in-

cluded Stanford faculty leaders in the field. They will be recognized at the Annual AHA Scientific Sessions -

Opening Session, on November 12, 2017 at Anaheim, California. Congratulations!

AHA Clinical Research Prize Award Robert Harrington, MD Arthur L. Bloomfield Pro-fessor of Medicine

AHA Distinguished Scientist Lecturer Marlene Rabinovitch, MD Dwight and Vera Dunlevie Professor of Pediatrics, Developmental Biology

AHA George E. Brown Memorial Lecturer Joseph C. Wu, MD, PhD Simon H. Stertzer Professor of Medicine and Radiology

On June 2017, Richard Popp, MD received the prestigious Albion Walter Hewlett Award, which honors an

“exceptional physician with ties to Stanford.” Dr. Popp, emeritus Professor of Medicine (Cardiovascular Medicine), gave a

Hewlett Award lecture “Understanding the Heart From the Outside-In."

Read more: https://medicine.stanford.edu/news/current-news/standard-news/Popp-Recieves-Hewlett.html

Richard Popp Receives Hewlett Award

Marlene Rabinovitch, MDNIH | Endothelial injury, BMPR2

dysfunction and macrophage activation cause EndMT and PAH

Matthew Porteus, MDCIRM | Genome editing to

correct cystic fibrosis mutations in airway stem cells

Guang Li, PhDNIH | Cellular and

molecular mechanism of atrial cardiomyocyte lineage commitment

Recently Awarded Projects

Adult heart failure patients for stem cell clinical studies

New Clinical Trials

The CANVAS Program The CANVAS Program (CANagliflozin CardioVascular Assessment Study) results presented at the

annual meeting of the American Diabetes Association in June 2017. The study investigated canagliflozin, a drug for patients with type 2 diabetes who were at high risk of cardiovascular events, in over 10,000 participants who were followed over an average of three years. The study showed that canagliflozin significantly reduced cardiovascular death, nonfatal myocardial infarction or nonfatal stroke by 14% compared with placebo. Canagiflozin increased the risk of amputation – usually at the level of toe or metatarsal.

Stanford CANVAS Program included Kenneth Mahaffey, MD, a member of the Steering Committee; Mark Hlatky, MD, and Nicholas Leeper, MD, members of the Cardiovascular Adjudication Committee; and Tara Chang, MD, MS, a member of the Renal Adjudication Com-mittee. The adjudication work was coordinated through the Stanford Center for Clinical Research (SCCR).

The trial manuscript was published in The New England Journal of Medicine simultaneously with the presentation of the results: http://www.nejm.org/doi/full/10.1056/NEJMoa1611925

Researchers at Stanford are studying the role of stem cells in patients with ischemic cardiomyopathy (ICM) and anthracycline-based chemotherapy induced cardiomy-opathy (AIC).

StEm cell iNjEction in CAncer survivors (SENECA), is a Phase 1 trial to test the safety and feasibility of allogenic mesenchymal stem cells (MSCs) in patients with AIC who are previous cancer survivors. Sinc therapy for AIC are limited, stem cells may offer an opportunity to restore their heart function. Adult cell therapy has been studied in pa-tients with heart disease with an excellent safety profile. SENECA is the first clinical study of cell therapy for AIC.

For more information, visit the SENECA Trial: https://clinicaltrials.gov/ct2/show/NCT02509156

Combination of meseNchymal and c-kit+ Cardiac stEm cells as Regenerative Therapy for Heart Failure (CONCERT HF), is a Phase 2 trial to examine the feasibility and effi-cacy of MSCs and c-kit+ cardiac stem cells (CSCs) in patients with ICM. CONCERT-HF is a randomized clinical trial that will evaluate heart function in four groups of patients: a) those treated with only their own MSCs, b) those treated with only their own CSCs, c) those treated with a combination of their own MSCs and CSCs, and d) those treated with placebo. All patients will be followed for one year.

For more information, visit the CONCERT HF: https://clinicaltrials.gov/ct2/show/NCT02501811

The National Heart, Lung, and Blood Insti-tute (NHLBI) established the Cardiovascular Cell Therapy Research Network (CCTRN), which includes key stem cell centers with expertise in conducting clinical trials for cardiovascular diseases. These centers in-clude Stanford University, Texas Heart In-stitute, University of Florida at Gainesville, Minneapolis Heart Institute Foundation, University of Louisville, University of Mi-ami, and the Vascular and Cardiac Center for Adult Stem Cell Therapy in Indianapolis, Indiana.

Further information on the CCTRN is available at: www.cctrn.org

Contact: Fouzia Khan, fouziak@stanford.edu or Phillip Yang, MD, phillip@stanford.edu

c v i . s ta n fo rd .e d u | 9

Joetsaroop Bagga, MD Candidate, 1st Year

Mentor: Tom Quertemous, MD Project: The role of vascular smooth muscle cell phenotype in coronary artery disease

Veronica Toro, MD Candidate, 1st Year Mentor: Alison Marsden, PhD Project: Construction of patient specific models from angiography for CABG surgery planning

Future Leaders in MedicineThe CVI received many meritorious and exciting research proposals this year and would like to thank all students and their mentors for submitting their research ideas. The committee has chosen to support tuition stipend for four students based on past excellence and future potential in the field of cardiovascular medicine. The awards will be presented at the annual iHeart luncheon on August 18, 2017.

Angela Zhang, MD PhD Candidate, 1st Year Mentor: Joseph Wu, MD PhD Project: Using nano straws to improve the delivery of CRISPR/Cas 9 system to cardiomyocytes

Xinyuan Lisa Zhang, MD Candidate, 2nd Year

Mentor: Anson Lee, MD Project: The role of epicardial-endocardial dissocia-tion in atrial fibrillation measured with a novel elec-trode sensor array with high spatiotemporal resolution

to the 2017 Dorothy Dee & Marjorie Helene Boring Trust Award recipients! Congratulations!

Successful Joint Cardiovascular Research Meeting at the 2017 Duke-Stanford Symposium

Scientists and faculty of Duke University and the Stanford University met over a two-day symposium to share research and collaborative opportunities. This inaugural event was co-hosted by Howard Rockman, MD of Duke Cardiovascular Institute and Joseph Wu, MD, PhD of the Stanford Cardiovascular Institute. Robert Lefkowitz, MD, Professor at Duke University and the 2012 Nobel Laureate presented the keynote with remarks from Duke Chancellor A. Eugene Washington, MD, Dean Mary Klotman, MD, and Provost Sally Kornbluth, PhD. To watch the recorded presentations, visit: http://tinyurl.com/DukeStanford.

Next Fall, The Stanford-Duke Cardiovascular Research Symposium will be held at the Stanford University, Li Ka Shing Center on October 15-16, 2018 with Brian Kobilka, PhD of Stanford University, 2012 Nobel Laureate presenting a keynote address.

c v i . s ta n fo rd .e d u | 10

National and Global Cardiovascular Conferences

AUGUST

Human Genetics in Atherosclerosis August 21, 2017 Stanford, CA Amgen-Stanford

European Society of Cardiology – Congress 2017 Aug 26-30, 2017 Barcelona, Spain ESC Congress

SEPTEMBER Council on Hypertension 2017 Scientific Sessions Sept 14-17, 2017 San Francisco, CA Hypertension

Heart Failure Society of America Annual Scientific Meeting Sept 16-19, 2017 Dallas, TX HFSA meeting

Stanford CVI Retreat Stanford-China Cardiovascular Research Symposium September 21-22, 2017 Stanford, CA CVI

Western Vascular Society Sept 23-26, 2017 Blaine, WA Western Vascular Society

NIH NHLBI Cardiovascular Regenerative Medicine Symposium September 27-28, 2017 Bethesda, MD Cardiovascular Regenerative Medicine

OCTOBER Update in Clinical Cardiology Harvard Medical School Oct 11-13, 2017 Boston, MA Clinical Cardiology

Vascular Biology (NAVBO – North American Vascular Biology) Oct 15-19, 2017 Pacific Grove, CA NAVBO

NOVEMBER 28th Annual Cardiovascular Interventions November 7-10, 2017 La Jolla, CA Cardiovascular Interventions

AHA Scientific Sessions 2017 Nov 11-15, 2017 Anaheim, CA AHA 2017

Controversies & Advances in the Treatment of Cardiovascular Disease: The Seventeenth in the Series 2017 November 16-17, 2017 Beverly Hills, CA Cardiovascular Disease

September 29, 2017 Lawrence H. and Roberta Cohn Lectureship

With a generous gift, the Lawrence H. and Roberta Cohn Lectureship was established in 2015. Dr. Lawrence Cohn was a San Francisco born pioneering cardiac surgeon, researcher, and medical education who performed more than 11,500 cardiac surgical operations and was a world-renowned expert in the field of valve repair and replacement surgery.

Joseph S. Coselli, MD Professor, Vice-Chair and Chief; Cullen Foundation Endowed Chair; Chief, Adult Cardiac Surgery, Texas Heart Institute; Department of Surgery, Baylor College of Medicine

March 6, 2018 Inaugural Steven M. Gootter Foundation Lectureship

The Gootter Foundation is working to defeat Sudden Cardiac Death (SCD). With their support, the Stanford Cardiovascular Institute has established its inaugural lectureship.

Mark E. Anderson, MD, PhD William Osler Professor of Medicine Director, Department of Medicine Johns Hopkins University Department of Medicine Physician in Chief, Johns Hopkins Hospital

SPECIAL LECTURES at STANFORD

For more information, contact: stanfordcvi@stanford.edu

| 11

September 6, 2017 (Wednesday) FLEMMING ØRNSKOV, MD, MPH

CEO of Shire Pharmaceuticals

September 12, 2017 (1 p.m.)ALVIN L. ROYSE, JD, CPA

Immediate Past Chairman of American Heart Association; Councilman, Town of Hillsborough; Retired Senior Partner Deloitt & Touche LLP

September 26, 2017 PHILLIP C. YANG, MD

Associate Professor of Medicine (Cardiovascular Medicine), Stanford

October 5, 2017 (Thursday)BRUCE D. GELB, MD

Director of the Center for Molecular Cardiology; Professor of Pediatrics and Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai

October 10, 2017 MICHAEL KAPILOFF, MD, PHD

Professor of Opthamology, Stanford

October 24, 2017 FRANCOIS HADDAD, MD

Clinical Associate Professor of Medicine (Cardiovascular Medicine), Stanford

October 31, 2017 WILSON TANG, MD

Professor of Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University

November 7, 2017GORDON M. KELLER, PHD

Director, McEwen Centre for Regenerative MedicineSenior Scientist, Ontario Cancer Institute

November 21, 2017JOSEPH HILL, MD, PHD

Distinguished Chair in Cardiovascular Diseases; Frank M. Ryburn Jr. Chair in Heart Research; Chief of Cardiology, University of Texas Southwestern

November 28, 2017MARK KAHN, MD

Professor of Medicine, University of Pennsylvania

December 5, 2017 FRANK W. SELLKE, MD

Karl E. Karlson, MD and Gloria A. Karlson Professor of Cardiothoracic Surgery, Brown Medical School and Lifespan Hospitals

December 12, 2017 JAMES K. LIAO, MD

Harold Hines Jr. Professor; Chief, Cardiology Section; Director, Physician Scientist Training Program University of Chicago, University of Chicago

January 23, 2018JAMES F. MARTIN, MD, PHD

Professor, Vivian L. Smith Chair in Regenerative Medicine, Baylor College of Medicine

February 13, 2018WALTER J. KOCH, PHD

William Wikoff Smith Endowed Chair in Cardiovascular Medicine; Professor and Chair, Pharmacology, Temple University

March 6, 2018Inaugural Steven M. Gootter Foundation LectureMARK E. ANDERSON, MD, PHD

William Osler Professor of Medicine; Chair, Department of Medicine, Johns Hopkins University

March 13, 2018KAM W. LEONG, PHD

Samuel Y. Sheng Professor; EiC, Biomaterials; Department of Biomedical Engineering, Columbia University

April 10, 2018THOMAS M. VONDRISKA, PHD

Professor of Anesthesiology, Medicine and Physiology, UCLA

April 17, 2018PEIPEI PING, PHD

Professor, Physiology, Medicine, Cardiology, and Bioinformatics, UCLA; Director, NIH BD2K Center of Excellence at UCLA; Director, NIH BD2K Centers-Coordination Center at UCLA

May 1, 2018GEOFFREY PITT, MD, PHD

Director of the Cardiovascular Research Institute; The Ida and Theo Rossi Distinguished Professor of Medicine, Weill Cornell Medical College

May 8, 2018ROBERT J. GROPLER, MD

Professor of Radiology, Medicine and Biomedical EngineeringSenior Vice-Chair and Division Director Radiological Sciences &Chief, Cardiovascular Imaging Laboratory Washington University School of Medicine

May 15, 2018BRADFORD C. BERK, MD, PHD

Distinguished University Professor in Medicine, Neurology, Pathology, and Pharmacology & Physiology;Director, University of Rochester Neurorestoration Institute University of Rochester Medical Center

May 22, 2018PETER LIBBY, MD

Mallinckrodt Professor of Medicine, Harvard Medical SchoolSenior Physician, Brigham and Women’s Hospital

June 5, 2018CHRISTINE MUMMERY, PHD

Professor of Developmental Biology, Chair Department of Anatomy & Embryology, Leiden University Medical Center

http://cvi.stanford.edu

Frontiers in Cardiovascular Science 2017-2018

Tuesdays 12:30 - 1:20 p.m. (unless otherwise noted), Li Ka Shing Center, LK130

c v i . s ta n fo rd .e d u | 12

Tobacco-related Disease Research Program (TRDRP) of California Amount of funding: $60K to $250K Letter of Intent (required): Aug 21, 2017 Deadline: Sept 25, 2017 TRDRP

Burroughs Wellcome Fund Amount of funding: $700K over 5 yrs Deadline: Oct 3, 2017 Burroughs

Stanford Child Health Research Institute (CHRI) Clinician Educator (CE) Grants Program Amount of funding: $25K for one year Deadline: Sept 1, 2017 CHRI

Fondation Leduq Transatlantic Networks of Excellence in Cardiovascular and Neurovascular Research Amount of funding: $6 over 5 years Deadline: LOI: Sept. 5, 2017 Deadline: Feb 14, 2018 Fondation Leduq

High Risk, High Reward Programs (DP1, DP2, TRA):

• NIH Director’s Pioneer Award (DP1)$3.5M (Sept. 1) RFA-RM-17-005

• NIH Director’s New Innovator Award(DP2) $1.5M (Sept. 8) RFA-RM-17-006

• NIH Transformative Research Award(no budget limit) (Sept. 15) RFA-RM-17-007

NHLBI Program Project Applications (P01) PAR-16-402 Amount of funding: $1,515,000 direct costs per year (5yr max) Deadline: Sept. 25, 2017 PAR-16-402

The Strategically Focused Research Vascular Disease Network Please note: Because only ONE center application is permitted from Stanford, Dr. Tom Quertermous, the Division Chief of Cardiovascular Medicine in the Department of Medicine, will facilitate/coordinate Stanford’s response to this RFP. Letter of Intent: Aug 1, 2017 Deadline: Sept. 26, 2017 AHA

The Pac-12 Student-Athlete Health and Well-Being Grant Program- 2018 Cycle Amount of funding: no limit, 3yrs maximum Internal proposal deadline: Aug 31, 2017 Deadline: Oct 1, 2017 (for selected proposals) Pac-12

NHLBI Basic Research in Calcific Aortic Valve Disease (R01) Deadline: October 18, 2017 RFA-HL-18-010

Spectrum Pilot Grants Amount of funding: $15-50K for 1 year Deadline: Anticipated to be end of 2017/early 2018 Spectrum Pilot Grants

NHLBI Bold New Bioengineering Methods and Approaches for Heart, Lung, Blood and Sleep Disorders and Diseases (R21) Amount of funding: $275K direct costs for 2 year period; 2 year maximum Deadline: January 10, 2018 RFA-HL-17-015

Faculty Funding Opportunities

Postdoctoral Funding Opportunities

Tobacco-related Disease Research Program (TRDRP) of California Amount of funding: $60K to $250K Letter of Intent (required): Aug 21, 2017 Deadline: Sept 25, 2017 TRDRP

Burroughs Wellcome Fund Amount of funding: $700K over 5 yrs Deadline: Oct 3, 2017 Burroughs

NHLBI Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01) Deadline: October 15, 2017 RFA-HL-16-006

Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Postdoctoral Fellows Deadline: December 8, 2017 PA-16-307

c v i . s ta n fo rd .e d u | 13

Clinical Biomarker & Phenotyping Core Lab (BPCL)

BPCL provides quantitative assessment of clinical cardiovascular phe-notypes for translational research and clinical trials. These cardiovas-cular phenotypes include evaluating cardiac structure and function, measuring carotid intimal thickness and arterial stiffness, and testing endothelial function and cardiopulmonary exercise testing.

In collaboration with the Human Immune Monitoring Center at Stanford and members of the Cardiovascular Institute, we also offer central blood processing and banking capabilities. In addition, we develop new biomarker platforms and imaging modalities.

Contact: Francois Haddad, MD / fhaddad@stanford.edu

CVI Cores

Normal and patient-derived reprogrammed cardiomyo-cytes are a tremendous resource for researchers and physicians here at Stanford and around the country. Un-derstanding the disease process directly at the popula-tion level and observing these cells as surrogates under a myriad conditions has the potential to be a game-chang-er for cardiovascular medical research.

To facilitate research in a dish that allows screening of new compounds or characterization of human disease phenotypes using cardiomyocytes, the Institute created a service by which de-identified peripheral blood mononuclear cell (PBMC) samples from selected patients can be sent to Stanford CVI for reprogramming free of cost.

SCVI biobank is supported in part by National Heart, Lung and Blood Institute (NHLBI) and the Stanford Cardiovascular Institute (CVI).

Stanford iPSC Biobank was recently mentioned in Nature Methods news: nature.com/nmeth/

journal/v12/n2/full/nmeth.3263.html.

Contact: Joseph Wu, MD, PhD / joewu@stanford.edu or Biobank manager, Yan Zhuge / yanzhuge@stanford.edu with any questions.

3DQ Imaging Laboratory Stanford’s 3DQ Imaging Laboratory de-velops new approaches to exploration, analysis and quantitative assessments of diagnostic images that result in new and/or more cost-effective diagnostic approach-es, and new techniques for the design and monitoring of therapy. The lab processes over 1,200 clinical cases to deliver relevant visualization and analysis of medical imag-ing data at Stanford.

The lab is co-directed by Dominik Fleis-chmann, MD, Roland Bammer, PhD and Sandy Napel, PhD.

Contact: Dominik Fleischmann, MD d.fleischmann@stanford.edu

Stanford CVI Human iPSC Biobank Service

Cardiovascular Pharma-cology (BioADD)The Cardiovascular Pharmacology/Bioma-terials and Advanced Drug Delivery (Bio-ADD) Laboratory is a cutting edge research facility that specializes in the creation of biomaterials and drug delivery agents. The lab lends its expertise toward design-ing and analyzing biomaterials, develop-ing drug delivery devices and formulations, pharmacokinetic and pharmacodynamic studies, and developing smart materials for biomedical applications. The CVI Cardio-vascular Pharmacology also offers trainings and lectures.

Contact: Jayakumar Rajadas, PhD jayraja@stanford.edu

CVI Clinical Trials Core The CVI Clinical Trials Core provides full spectrum of support to CVI members and their clinical tri-als. The coordinators has extensive clinical research experience in both industry and academia. The team provides services and support to principal investigators and sponsors, including:

Contact: Ed Finn, Clinical Trials Manager or Hoa Ly, Clinical Research Coordinator at (650) 498-6279

• Consultation

• Study start-up management, includingIRB applications, budget development

• Subject recruitment, site visits, andfollow-ups (AE reporting and queries)

• Data management

• Regulatory compliance and documen-tation

• Closeout

c v i . s ta n fo rd .e d u | 14

Communication is at the heart of scientific advancement and innovation. This quarter, the Stanford Cardiovascular Institute members published over 267 original manuscripts and reviews, further contributing to our understanding of cardiovascular biology and disease. Here, we highlight selected manuscripts by our members.

Member Publications

JULY

Navigating the Future of Cardiovascular Drug Development-Leveraging Novel

Approaches to Drive Innovation and Drug Discovery: Summary of Findings from

the Novel Cardiovascular Therapeutics Conference. Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Kha-

koo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz

GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT. Cardiovasc Drugs Ther. 2017

Jul 22.

Alternative Strategy for Biventricular Assist Device in an Infant With Hypertro-

phic Cardiomyopathy. Dykes JC, Reinhartz O, Almond CS, Yarlagadda V, Murray

J, Rosenthal DN, Maeda K. Ann Thorac Surg. 2017 Aug;104(2):e185-e186.

Unreliable Observations from a Confounded Analysis of a Skewed Database.

Steg PG, Harrington RA, Himmelmann A, James SK, Pieper KS, Wallentin L. Am J

Med. 2017 Aug;130(8):e355-e356.

Spatial relationship of sites for atrial fibrillation drivers and atrial tachycardia

in patients with both arrhythmias. Baykaner T, Zaman JAB, Rogers AJ, Navara R,

AlHusseini M, Borne RT, Park S, Wang PJ, Krummen DE, Sauer WH, Narayan SM.

Int J Cardiol. 2017 Jul 14. S0167-5273(17)31816-8.

Bioacoustic-enabled patterning of human iPSC-derived cardiomyocytes into 3D

cardiac tissue. Serpooshan V, Chen P, Wu H, Lee S, Sharma A, Hu DA, Venkatra-

man S, Ganesan AV, Usta OB, Yarmush M, Yang F, Wu JC, Demirci U, Wu SM. Bio-

materials. 2017 Jul;131:47-57.

Identification of a hybrid myocardial zone in the mammalian heart after birth.

Tian X, Li Y, He L, Zhang H, Huang X, Liu Q, Pu W, Zhang L, Li Y, Zhao H, Wang

Z, Zhu J, Nie Y, Hu S, Sedmera D, Zhong TP, Yu Y, Zhang L, Yan Y, Qiao Z, Wang

QD, Wu SM, Pu WT, Anderson RH, Zhou B. Nat Commun. 2017 Jul 20;8(1):87.

Induced Pluripotent Stem Cell-Derived Endothelial Cells in Insulin Resis-

tance and Metabolic Syndrome. Carcamo-Orive I,  Huang NF,  Quertermous T, Knowles JW. Arterioscler Thromb Vasc Biol. 2017 Jul 20.

Accuracy of Fractional Flow Reserve Measurements in Clinical Practice: Observa-

tions From a Core Laboratory Analysis. Matsumura M, Johnson NP, Fearon WF,

Mintz GS, Stone GW, Oldroyd KG, De Bruyne B, Pijls NHJ, Maehara A, Jeremias A.

JACC Cardiovasc Interv. 2017 Jul 24;10(14):1392-1401.

Exercise Training Improves Ventilatory Efficiency in Patients With a Small Ab-

dominal Aortic Aneurysm: A RANDOMIZED CONTROLLED STUDY. Lima RM, Vain-

shelboim B, Ganatra R, Dalman R, Chan K, Myers J. J Cardiopulm Rehabil Prev.

2017 Jul 19.

The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-

Jagged1-Notch pathway. Wen Z, Shen Y, Berry G, Shahram F, Li Y, Watanabe R,

Liao YJ, Goronzy JJ, Weyand CM. Sci Transl Med. 2017 Jul 19;9(399).

CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors.

Bak RO, Porteus MH. Cell Rep. 2017 Jul 18;20(3):750-756.

Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in

a new light. Trivedi DV, Adhikari AS, Sarkar SS, Ruppel KM, Spudich JA. Biophys

Rev. 2017 Jul 17.

Discovery of Novel Human Gene Regulatory Modules from Gene Co-expression

and Promoter Motif Analysis. Ma S, Snyder M, Dinesh-Kumar SP. Sci Rep. 2017

Jul 17;7(1):5557.

Bridge to Success: A Better Method of Cryoablation for Atrioventricular Nodal

Reentrant Tachycardia in Children. Reddy CD, Ceresnak SR, Motonaga KS, Ava-

sarala K, Feller C, Trela A, Hanisch D, Dubin AM. Heart Rhythm. 2017 Jul 14.

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan

for the integrated analyses of the CANVAS and CANVAS-R trials. Neal B, Perkov-

ic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, Shaw W, Law G, Walton MK,

Rosenthal N, de Zeeuw D, Matthews DR; CANVAS Program collaborative group.

Diabetes Obes Metab. 2017 Jul;19(7):926-935.

Anisotropic microfibrous scaffolds enhance the organization and function of

cardiomyocytes derived from induced pluripotent stem cells. Wanjare M, Hou L, Nakayama KH, Kim JJ, Mezak NP, Abilez OJ, Tzatzalos E, Wu JC, Huang NF.

Biomater Sci. 2017 Jul 17.

The importance of capillary density-stroke work mismatch for right ventricular

adaptation to chronic pressure overload. Noly PE, Haddad F, Arthur-Ataam J,

Langer N, Dorfmüller P, Loisel F, Guihaire J, Decante B, Lamrani L, Fadel E, Mer-

cier O. J Thorac Cardiovasc Surg. 2017 Jun 15.

Targeting weight loss interventions to reduce cardiovascular complications of

type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous

treatment effects in the Look AHEAD trial. Baum A, Scarpa J, Bruzelius E, Tamler

R, Basu S, Faghmous J. Lancet Diabetes Endocrinol. 2017 Jul 12.

Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American

Patients With Heart Failure. Ziaeian B, Fonarow GC, Heidenreich PA. JACC Heart

Fail. 2017 Jul 12. S2213-1779(17)30278-0.

Comparison of Non-Coding RNAs in Exosomes and Functional Efficacy of Human

Embryonic Stem Cell- Versus Induced Pluripotent Stem Cell-Derived Cardiomyo-

cytes. Lee WH, Chen W, Shao NY, Xiao D, Qin X, Baker N, Bae HRM, Shukla P, Wu

H, Kodo K, Ong SG, Wu JC. Stem Cells. 2017 Jul 14.

Accelerometry: Improving Objective Assessments of Therapeutic Impact in Pedi-

atric Pulmonary Arterial Hypertension. Austin ED, Feinstein JA. Am J Respir Crit

Care Med. 2017 Jul 15;196(2):127-129.

Assessment of bioresorbable scaffold with a novel high-definition 60 MHz IVUS

imaging system: Comparison with 40-MHz IVUS referenced to optical coher-

ence tomography. Okada K, Kitahara H, Mitsutake Y, Tanaka S, Kimura T, Yock PG, Fitzgerald PJ, Ikeno F, Honda Y. Catheter Cardiovasc Interv. 2017 Jul 14.

DNA binding drives the association of BRG1/hBRM bromodomains with nucleo-

somes. Morrison EA, Sanchez JC, Ronan JL, Farrell DP, Varzavand K, Johnson JK,

Gu BX, Crabtree GR, Musselman CA. Nat Commun. 2017 Jul 14;8:16080.

c v i . s ta n fo rd .e d u | 15

Comprehensive Multi-Dimensional MRI for the Simultaneous Assessment of Car-

diopulmonary Anatomy and Physiology. Cheng JY, Zhang T, Alley MT, Uecker M,

Lustig M, Pauly JM, Vasanawala SS. Sci Rep. 2017 Jul 13;7(1):5330.

Using Commercial Programs for Lifestyle  Intervention: Not Reinventing the

Wheel. Maron DJ, Sandhu AT. J Am Coll Cardiol. 2017 Jul 18;70(3):328-330.

Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban

Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial

Substudy. Gibson CM, Korjian S, Chi G, Daaboul Y, Jain P, Arbetter D, Goldhaber

SZ, Hull R, Hernandez AF, Lopes RD, Gold A, Cohen AT, Harrington RA; APEX In-

vestigators. J Am Heart Assoc. 2017 Jul 11;6(7).

Large-scale physical activity data reveal worldwide activity inequal-

ity. Althoff T, Sosič R, Hicks JL, King AC, Delp SL, Leskovec J. Nature. 2017 Jul

20;547(7663):336-339.

Myocardial Bridges on Coronary Computed Tomography Angiography-Corre-

lation with Intravascular Ultrasound and Fractional Flow Reserve. Forsdahl

SH, Rogers IS, Schnittger I, Tanaka S, Kimura T, Pargaonkar VS, Chan FP, Fleis-chmann D, Tremmel JA, Becker HC. Circ J. 2017 Jul 7.

Contractile reserve and cardiopulmonary exercise parameters in patients with

dilated cardiomyopathy, the two dimensions of exercise testing. Moneghetti KJ,

Kobayashi Y, Christle JW, Ariyama M, Vrtovec B, Kouznetsova T, Wilson A, Ashley

E, Wheeler MT, Myers J, Haddad F. Echocardiography. 2017 Jul 6.

Gaining comprehensive biological insight into the transcriptome by perform-

ing a broad-spectrum RNA-seq analysis. Sahraeian SME, Mohiyuddin M, Sebra

R, Tilgner H, Afshar PT, Au KF, Bani Asadi N, Gerstein MB, Wong WH, Snyder MP,

Schadt E, Lam HYK. Nat Commun. 2017 Jul 5;8(1):59.

Risk and Consequences of Atrial Fibrillation: It’s in the Jeans, Not the Genes.

Turakhia MP. JAMA Cardiol. 2017 Jul 5.

Microfluidic-based mini-metagenomics enables discovery of novel microbial lin-

eages from complex environmental samples. Yu FB, Blainey PC, Schulz F, Woyke

T, Horowitz MA, Quake SR. Elife. 2017 Jul 5;6.

Molecular Mechanisms of Sodium-Sensitive Hypertension in the Metabolic Syn-

drome. Nizar JM, Bhalla V. Curr Hypertens Rep. 2017 Aug;19(8):60.

New Generalized Equation for Predicting Maximal Oxygen Uptake (from the

Fitness Registry and the Importance of Exercise National Database). Kokkinos

P, Kaminsky LA, Arena R, Zhang J,  Myers J. Am J Cardiol. 2017 Jun 1. S0002-

9149(17)30873-1.

Myocardial bridges: Overview of diagnosis and management. Rogers IS, Trem-mel JA, Schnittger I. Congenit Heart Dis. 2017 Jul 3.

Associations Between Self-Reported Physical Activity and Physical Performance

Measures Over Time in Postmenopausal Women: The Women’s Health Initiative.

Laddu DR, Wertheim BC, Garcia DO, Brunner R, Groessl E, Shadyab AH, Going SB,

LaMonte MJ, Cannell B, LeBoff MS, Cauley JA, Thomson CA, Stefanick ML. J Am

Geriatr Soc. 2017 Jul 4.

Changes in E-cadherin rigidity sensing regulate cell adhesion. Collins C, Denisin

AK, Pruitt BL, Nelson WJ. Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5835-

E5844.

E-cadherin and LGN align epithelial cell divisions with tissue tension indepen-

dently of cell shape. Hart KC, Tan J, Siemers KA, Sim JY, Pruitt BL, Nelson WJ,

Gloerich M. Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5845-E5853.

Needs-Based Innovation in Interventional Radiology: The Biodesign Process.

Steinberger JD, Denend L, Azagury DE, Brinton TJ, Makower J, Yock PG. Tech

Vasc Interv Radiol. 2017 Jun;20(2):84-89.

Thalidomide treatment prevents chronic graft rejection after aortic transplanta-

tion in rats. Miller KK, Wang D, Hu X, Hua X, Deuse T, Neofytou E, Renne T, Velden

J, Reichenspurner H, Schrepfer S, Bernstein D. Transpl Int. 2017 Jul 3.

Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. Jokerst

JV, Cauwenberghs N, Kuznetsova T, Haddad F, Sweeney T, Hou J, Rosenberg-

Hasson Y, Zhao E, Schutt R, Bolli R, Traverse JH, Pepine CJ, Henry TD, Schulman

IH, Moyé L, Taylor DA, Yang PC. Sci Rep. 2017 Jun 30;7(1):4419.

Single-molecule analysis of ligand efficacy in β2AR-G-protein activation. Grego-

rio GG, Masureel M, Hilger D, Terry DS, Juette M, Zhao H, Zhou Z, Perez-Aguilar

JM, Hauge M, Mathiasen S, Javitch JA, Weinstein H, Kobilka BK, Blanchard SC.

Nature. 2017 Jul 6;547(7661):68-73.

Association Between Previous Use of Antiplatelet Therapy and Intracerebral

Hemorrhage Outcomes. Khan NI, Siddiqui FM, Goldstein JN, Cox M, Xian Y, Mat-

souaka RA, Heidenreich PA, Peterson ED, Bhatt DL, Fonarow GC, Schwamm LH,

Smith EE. Stroke. 2017 Jul;48(7):1810-1817.

Leveraging Human Genetics to Understand the Relation of LDL Cholesterol with

Type 2 Diabetes. Ingelsson E, Knowles JW. Clin Chem. 2017 Jul;63(7):1187-1189.

A multicenter review of ablation in the aortic cusps in young people. Nguyen MB,

Ceresnak SR, Janson CM, Fishberger SB, Love BA, Blaufox AD, Motonaga KS, Du-bin AM, Nappo L, Pass RH. Pacing Clin Electrophysiol. 2017 Jul;40(7):798-802.

Contractile force generation by 3D hiPSC-derived cardiac tissues is enhanced by

rapid establishment of cellular interconnection in matrix with muscle-mimick-

ing stiffness. Lee S, Serpooshan V, Tong X, Venkatraman S, Lee M, Lee J, Chiriki-

an O, Wu JC, Wu SM, Yang F. Biomaterials. 2017 Jul;131:111-120.

Predictive value of device-derived activity level for short-term outcomes in MA-

DIT-CRT. Jamé S, Kutyifa V, Polonsky B, McNitt S, Al-Ahmad A, Moss AJ, Zareba

W, Wang PJ. Heart Rhythm. 2017 Jul;14(7):1081-1086.

A multicenter study of the impella device for mechanical support of the systemic

circulation in pediatric and adolescent patients. Dimas VV, Morray BH, Kim DW,

Almond CS, Shahanavaz S, Tume SC, Peng LF, McElhinney DB, Justino H. Cath-

eter Cardiovasc Interv. 2017 Jul;90(1):124-129.

At the threshold of a new era in pediatric ventricular assist device therapy. Mae-da K. J Thorac Cardiovasc Surg. 2017 Jul;154(1):301-302.

Incremental value of right heart metrics and exercise performance to well-

validated risk scores in dilated cardiomyopathy. Moneghetti KJ, Giraldeau G,

Wheeler MT, Kobayashi Y, Vrtovec B, Boulate D, Kuznetsova T, Schnittger I, Wu JC, Myers J, Ashley E, Haddad F. European Heart Journal - Cardiovascular Im-

aging, jex187, Jul 2017.

Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic

Testing. Knowles JW, Rader DJ, Khoury MJ. JAMA. 2017;318(4):381–382.

c v i . s ta n fo rd .e d u | 16

JUNE Genome-Wide Temporal Profiling of Transcriptome and Open-Chromatin of Ear-

ly Cardiomyocyte Differentiation Derived From hiPSCs and hESCs. Liu Q, Jiang

C, Xu J, Zhao M, Van Bortle K, Cheng X, Wang G, Chang HY, Wu JC, Snyder MP.

Circ Res. 2017 Jun 29.

Treating Specialty and Outcomes in Newly  Diagnosed Atrial Fibrillation: From

the TREAT-AF Study. Perino AC, Fan J, Schmitt SK, Askari M, Kaiser DW, Deshmukh

A, Heidenreich PA, Swan C, Narayan SM, Wang PJ, Turakhia MP. J Am Coll Car-

diol. 2017 Jul 4;70(1):78-86.

Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront

Therapy in Scleroderma Pulmonary Arterial Hypertension. Mercurio V, Mukher-

jee M, Tedford RJ, Zamanian RT, Khair RM, Sato T, Minai OA, Torres F, Girgis RE,

Chin K, Damico R, Kolb TM, Mathai SC, Hassoun PM. Am J Respir Crit Care Med.

2017 Jun 29.

Immune Checkpoint Function of CD85j in CD8 T Cell Differentiation and Aging.

Gustafson CE, Qi Q, Hutter-Saunders J, Gupta S, Jadhav R, Newell E, Maecker

H, Weyand CM, Goronzy JJ. Front Immunol. 2017 Jun 14;8:692.

RBM25 is a global splicing factor promoting inclusion of alternatively spliced ex-

ons and is itself regulated by lysine mono-methylation. Carlson SM, Soulette CM,

Yang Z, Elias JE, Brooks AN, Gozani O. J Biol Chem. 2017 Jun 27.

Cardiovascular Testing and Clinical Outcomes in Emergency Department Pa-

tients With Chest Pain. Sandhu AT, Heidenreich PA, Bhattacharya J, Bundorf MK.

JAMA Intern Med. 2017 Jun 26.

Relationship between simple markers of insulin resistance and coronary artery

calcification. Reaven GM, Knowles JW, Leonard D, Barlow CE, Willis BL, Haskell WL, Maron DJ. J Clin Lipidol. 2017 Jun 6. S1933-2874(17)30339-2.

The relationship between cardiac endothelium and fibroblasts: it’s complicated.

Karra R, Walter AO, Wu SM. J Clin Invest. 2017 Jun 26.

Quantitative EEG Metrics Differ Between Outcome Groups and Change Over the

First 72 h in Comatose Cardiac Arrest Patients. Wiley SL, Razavi B, Krishnamohan

P, Mlynash M, Eyngorn I, Meador KJ, Hirsch KG. Neurocrit Care. 2017 Jun 23.

Long-read genome sequencing identifies causal structural variation in a Mende-

lian disease. Merker JD, Wenger AM, Sneddon T, Grove M, Zappala Z, Fresard L,

Waggott D, Utiramerur S, Hou Y, Smith KS, Montgomery SB, Wheeler M, Buchan

JG, Lambert CC, Eng KS, Hickey L, Korlach J, Ford J, Ashley EA. Genet Med. 2017

Jun 22.

Tandem malonate-based glucosides (TMGs) for membrane protein structural

studies. Hussain H, Mortensen JS, Du Y, Santillan C, Ribeiro O, Go J, Hariharan P,

Loland CJ, Guan L, Kobilka BK, Byrne B, Chae PS. Sci Rep. 2017 Jun 21;7(1):3963.

Bioengineered constructs combined with exercise enhance stem cell-mediated

treatment of volumetric muscle loss. Quarta M, Cromie M, Chacon R, Blonigan

J, Garcia V, Akimenko I, Hamer M, Paine P, Stok M, Shrager JB, Rando TA. Nat

Commun. 2017 Jun 20;8:15613.

An innovative biologic system for photon-powered myocardium in the ischemic

heart. Cohen JE, Goldstone AB, Paulsen MJ, Shudo Y, Steele AN, Edwards BB,

Patel JB, MacArthur JW Jr, Hopkins MS, Burnett CE, Jaatinen KJ, Thakore AD,

Farry JM, Truong VN, Bourdillon AT, Stapleton LM, Eskandari A, Fairman AS,

Hiesinger W, Esipova TV, Patrick WL, Ji K, Shizuru JA, Woo YJ. Sci Adv. 2017 Jun

14;3(6):e1603078.

High-throughput screening technologies for enzyme engineering. Longwell CK,

Labanieh L, Cochran JR. Curr Opin Biotechnol. 2017 Jun 15;48:196-202.

Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming

Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Ar-

terial Hypertension. Tojais NF, Cao A, Lai YJ, Wang L, Chen PI, Alcazar MAA, de

Jesus Perez V, Hopper RK, Rhodes CJ, Bill MA, Sakai LY, Rabinovitch M. Arterio-

scler Thromb Vasc Biol. 2017 Jun 15.

Management and outcomes of symptomatic abdominal aortic aneurysms during

the past 20 years. Chandra V, Trang K, Virgin-Downey W, Tran K, Harris EJ, Dal-man RL, Lee JT, Mell MW. J Vasc Surg. 2017 Jun 12. S0741-5214(17)31140-0.

Daratumumab yields rapid and deep hematologic responses in patients with

heavily pretreated AL amyloidosis. Kaufman GP, Schrier SL, Lafayette RA, Arai

S, Witteles RM, Liedtke M. Blood. 2017 Jun 14.

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Elec-

tronic Devices: Observations From the ROCKET AF Trial. Leef GC, Hellkamp AS,

Patel MR, Becker RC, Berkowitz SD, Breithardt G, Halperin JL, Hankey GJ, Hacke

W, Nessel CC, Singer DE, Fox KAA,  Mahaffey KW, Piccini JP. J Am Heart Assoc.

2017 Jun 14;6(6).

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. Neal B,

Perkovic V,  Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G,

Desai M, Matthews DR; CANVAS Program Collaborative Group. N Engl J Med. 2017

Jun 12.

Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immu-

nity. Watanabe R, Shirai T, Namkoong H, Zhang H, Berry GJ, Wallis BB, Schaef-

gen B, Harrison DG, Tremmel JA, Giacomini JC, Goronzy JJ, Weyand CM. J Clin

Invest. 2017 Jun 30;127(7):2725-2738.

Brief Report: External Beam Radiation Therapy for the Treatment of Human

Pluripotent Stem Cell-Derived Teratomas. Lee AS, Tang C, Hong WX, Park S,

Bazalova-Carter M, Nelson G, Sanchez-Freire V, Bakerman I, Zhang W, Neofytou E,  Connolly AJ, Chan CK, Graves EE,  Weissman IL, Nguyen PK,  Wu JC. Stem

Cells. 2017 Jun 10.

Exercise reestablishes autophagic flux and mitochondrial quality control in

heart failure. Campos JC, Queliconi BB, Bozi LHM, Bechara LRG, Dourado PMM,

Andres AM, Jannig PR, Gomes KMS, Zambelli VO, Rocha-Resende C, Guatimosim

S, Brum PC,  Mochly-Rosen D, Gottlieb RA, Kowaltowski AJ, Ferreira JCB. Au-

tophagy. 2017 Jun 9:0.

Stem Cell Therapy: Healing or Hype? Why Stem Cell Delivery Doesn’t Work.

Steele AN, MacArthur JW, Woo YJ. Circ Res. 2017 Jun 9;120(12):1868-1870.

Angiotensin-Converting Enzyme Inhibition Early After Heart Transplantation.

Fearon WF, Okada K, Kobashigawa JA, Kobayashi Y, Luikart H, Sana S, Daun T,

Chmura SA, Sinha S, Cohen G, Honda Y, Pham M, Lewis DB, Bernstein D, Yeung AC, Valantine HA, Khush K. J Am Coll Cardiol. 2017 Jun 13;69(23):2832-2841.

Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pul-

monary Arterial Hypertension: Comparison With Validated Models. Amsallem M,

Sweatt AJ, Aymami MC, Kuznetsova T, Selej M, Lu H, Mercier O, Fadel E, Schnitt-ger I, McConnell MV, Rabinovitch M, Zamanian RT, Haddad F. Circ Cardiovasc

Imaging. 2017 Jun;10(6).

Associations of Glycemic Control With Cardiovascular Outcomes Among US

Hemodialysis Patients With Diabetes Mellitus. Rhee JJ, Zheng Y, Montez-Rath

ME, Chang TI, Winkelmayer WC. J Am Heart Assoc. 2017 Jun 7;6(6).

c v i . s ta n fo rd .e d u | 17

The Conundrum of Equitable Organ Allocation in Heart Transplantation: The

Moving Target of Candidate Risk Score. Potena L,  Khush KK. Transplantation.

2017 Jun 6.

Trajectories of the relationships of physical activity with body composition

changes in older men: the MrOS study. Laddu DR, Cawthon PM, Parimi N, Hoff-

man AR, Orwoll E, Miljkovic I, Stefanick ML; Osteoporotic Fractures in Men Study

Research Group. BMC Geriatr. 2017 Jun 5;17(1):119.

Spectral Doppler Waveforms for Diagnosis of Appendicitis: Potential Utility of

Point Peak Systolic Velocity and Resistive Index Values. Shin LK, Jeffrey RB, Ber-ry GJ, Olcott EW. Radiology. 2017 Jun 5:162251.

YY1 Expression Is Sufficient for the Maintenance of Cardiac Progenitor Cell State.

Gregoire S, Li G, Sturzu AC, Schwartz RJ, Wu SM. Stem Cells. 2017 Jun 5.

Echocardiography-Derived Left Ventricular Outflow Tract Gradient and Left Ven-

tricular Posterior Wall Thickening Are Associated with Outcomes for Anatomic

Repair in Congenitally Corrected Transposition of the Great Arteries. Moodley S,

Balasubramanian S, Tacy TA, Chan F, Hanley FL, Punn R. J Am Soc Echocardiogr.

2017 Jun 1. S0894-7317(17)30219-5.

Cangrelor reduces the risk of ischemic complications in patients with single-ves-

sel and multi-vessel disease undergoing percutaneous coronary intervention:

Insights from the CHAMPION PHOENIX trial. Abnousi F, Sundaram V, Yong CM,

Prats J, Deliargyris EN, Stone GW, Hamm CW, Steg PG, Gibson CM, White HD,

Price MJ, Généreux P, Desai M, Yang L, Ding VY, Harrington RA, Bhatt DL, Ma-haffey KW. Am Heart J. 2017 Jun;188:147-155.

A novel protein-engineered hepatocyte growth factor analog released via a

shear-thinning injectable hydrogel enhances post-infarction ventricular func-

tion. Steele AN, Cai L, Truong VN, Edwards BB, Goldstone AB, Eskandari A, Mitch-

ell AC, Marquardt LM, Foster AA, Cochran JR, Heilshorn SC, Woo YJ. Biotechnol

Bioeng. 2017 Jun 2.

Cardiorespiratory Fitness and Reclassification of Risk for Incidence of Heart Fail-

ure: The Veterans Exercise Testing Study. Myers J, Kokkinos P, Chan K, Dandekar

E, Yilmaz B, Nagare A, Faselis C, Soofi M. Circ Heart Fail. 2017 Jun;10(6).

Relationship among age, insulin resistance, and blood pressure. Jung CH,

Jung SH, Lee B, Rosenberg M, Reaven GM, Kim SH. J Am Soc Hypertens. 2017

Jun;11(6):359-365.e2.

Ventricular pacing in single ventricles-A bad combination. Bulic A, Zimmerman

FJ, Ceresnak SR, Shetty I, Motonaga KS, Freter A, Trela AV, Hanisch D, Russo L,

Avasarala K, Dubin AM. Heart Rhythm. 2017 Jun;14(6):853-857.

Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-

6-Related Impairment of Bone Marrow Function. Shahrivari M, Wise E, Resende

M, Shuster JJ, Zhang J, Bolli R, Cooke JP, Hare JM, Henry TD, Khan A, Taylor DA,

Traverse JH,  Yang PC, Pepine CJ, Cogle CR; Cardiovascular Cell Therapy Re-

search Network (CCTRN). Circ Res. 2017 Jun 9;120(12):1947-1957.

The myosin mesa and the basis of hypercontractility caused by hypertro-

phic cardiomyopathy mutations. Nag S, Trivedi DV, Sarkar SS, Adhikari AS,

Sunitha MS, Sutton S, Ruppel KM,  Spudich JA. Nat Struct Mol Biol. 2017

Jun;24(6):525-533.

Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index

(from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once

Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for

Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). Balla SR, Cyr

DD, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Hal-

perin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR. Am

J Cardiol. 2017 Jun 15;119(12):1989-1996.

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibi-

tors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular

Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): In-

sights From the Department of Veterans Affairs. Virani SS, Akeroyd JM, Nambi

V, Heidenreich PA, Morris PB, Nasir K, Michos ED, Bittner VA, Petersen LA, Bal-

lantyne CM. Circulation. 2017 Jun 20;135(25):2572-2574.

Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores

in Patients With Heart Failure (from the Outcomes Registry for Better Informed

Treatment of Atrial Fibrillation [ORBIT-AF]). Cherian TS, Shrader P, Fonarow GC,

Allen LA, Piccini JP, Peterson ED, Thomas L, Kowey PR, Gersh BJ, Mahaffey KW.

Am J Cardiol. 2017 Jun 1;119(11):1763-1769.

Cardiorespiratory fitness, physical activity and cancer mortality in men. Vain-

shelboim B, Müller J, Lima RM, Nead KT, Chester C, Chan K, Kokkinos P, Myers J.

Prev Med. 2017 Jul;100:89-94.

Variable clinical course of identical twin neonates with Alström syndrome pre-

senting coincidentally with dilated cardiomyopathy. Hollander SA, Alsaleh N,

Ruzhnikov M, Jensen K,  Rosenthal DN, Stevenson DA, Manning M. Am J Med

Genet A. 2017 Jun;173(6):1687-1689.

Tachycardia cycle and atrioventricular nodal conduction properties in children

with supraventricular tachycardia. Mills M, Dubin AM, Motonaga KS, Ceresnak

SR. Pacing Clin Electrophysiol. 2017 Jun;40(6):745-747.

A comparison of methods for determining the ventilatory threshold: impli-

cations for surgical risk stratification. Vainshelboim B, Rao S, Chan K, Lima

RM, Ashley EA, Myers J. Can J Anaesth. 2017 Jun;64(6):634-642.

Integrin-mediated traction force enhances paxillin molecular associations and

adhesion dynamics that increase the invasiveness of tumor cells into a three-

dimensional extracellular matrix. Mekhdjian AH, Kai F, Rubashkin MG, Prahl

LS, Przybyla LM, McGregor AL, Bell ES, Barnes JM, DuFort CC, Ou G, Chang AC,

Cassereau L, Tan SJ, Pickup MW, Lakins JN, Ye X, Davidson MW, Lammerding J,

Odde DJ, Dunn AR, Weaver VM. Mol Biol Cell. 2017 Jun 1;28(11):1467-1488.

Left atrial function and phenotypes in asymmetric hypertrophic cardiomyopa-

thy. Kobayashi Y, Wheeler M, Finocchiaro G, Ariyama M, Kobayashi Y, Perez MV,

Liang D, Kuznetsova T,  Schnittger I, Ashley E,  Haddad F. Echocardiography.

2017 Jun;34(6):843-850.

Effect of Metabolic Syndrome on the Mobility Benefit of a Structured Physical

Activity Intervention-The Lifestyle Interventions and Independence for Elders

Randomized Clinical Trial. Botoseneanu A, Chen H, Ambrosius WT, Allore HG, An-

ton S, Folta SC, King AC, Nicklas BJ, Spring BJ, Strotmeyer ES, Gill TM; LIFE Study

Group. J Am Geriatr Soc. 2017 Jun;65(6):1244-1250.

c v i . s ta n fo rd .e d u | 18

Functional status of United States children supported with a left ventricular as-

sist device at heart transplantation. Bulic A, Maeda K, Zhang Y, Chen S, McElhin-

ney DB, Dykes JC, Hollander AM, Hollander SA, Murray J, Reinhartz O, Gowan

MA, Rosenthal DN, Almond CS. J Heart Lung Transplant. 2017 Aug;36(8):890-896.

Biatrial connection of partial anomalous pulmonary venous return. Wata-

nabe N, Fallah H, Pugh C,  Nasirov T. Asian Cardiovasc Thorac Ann. 2017

Jun;25(5):381-382.

Peripheral Endothelial Function After Arterial Switch Operation for D-looped

Transposition of the Great Arteries. Sun HY, Stauffer KJ, Nourse SE, Vu C,  Se-lamet Tierney ES. Pediatr Cardiol. 2017 Jun;38(5):1010-1015.

Effects of Transendocardial CD34+ Cell Transplantation on Diastolic Parameters

in Patients with Nonischemic Dilated Cardiomyopathy. Bervar M, Kozelj M, Po-

glajen G, Sever M, Zemljic G, Frljak S, Cukjati M, Cernelc P, Haddad F, Vrtovec B.

Stem Cells Transl Med. 2017 Jun;6(6):1515-1521.

Quantitative Analysis of Synthetic Cell Lineage Tracing Using Nuclease Barcod-

ing. Schmidt ST, Zimmerman SM, Wang J, Kim SK, Quake SR. ACS Synth Biol.

2017 Jun 16;6(6):936-942.

Clinical and pathological evolution of giant cell arteritis: a prospective study

of follow-up temporal artery biopsies in 40 treated patients. Maleszewski JJ,

Younge BR, Fritzlen JT, Hunder GG, Goronzy JJ, Warrington KJ, Weyand CM. Mod

Pathol. 2017 Jun;30(6):788-796.

Two Independent Mapping Techniques Identify Rotational Activity Patterns at

Sites of Local Termination During Persistent Atrial Fibrillation. Alhusseini M, Vid-

mar D, Meckler GL, Kowalewski CA, Shenasa F, Wang PJ, Narayan SM, Rappel

WJ. J Cardiovasc Electrophysiol. 2017 Jun;28(6):615-622.

Bringing new dimensions to drug discovery screening: impact of cellular stimu-

lation technologies. Molokanova E, Mercola M, Savchenko A. Drug Discov Today.

2017 Jul;22(7):1045-1055.

Investigating the value of right heart echocardiographic metrics for detection

of pulmonary hypertension in patients with advanced lung disease. Amsallem

M, Boulate D, Kooreman Z,  Zamanian RT, Fadel G,  Schnittger I, Fadel E,  Mc-Connell MV, Dhillon G, Mercier O,  Haddad F. Int J Cardiovasc Imaging. 2017

Jun;33(6):825-835.

The Influence of Race and Common Genetic Variations on Outcomes After Pe-

diatric Heart Transplantation. Green DJ, Brooks MM, Burckart GJ, Chinnock RE,

Canter C, Addonizio LJ, Bernstein D, Kirklin JK, Naftel DC, Girnita DM, Zeevi A,

Webber SA. Am J Transplant. 2017 Jun;17(6):1525-1539.

Warfarin utilisation and anticoagulation control in patients with atrial fibril-

lation and chronic kidney disease. Yang F, Hellyer JA, Than C, Ullal AJ, Kaiser

DW, Heidenreich PA, Hoang DD, Winkelmayer WC, Schmitt S, Frayne SM, Phibbs

CS, Turakhia MP. Heart. 2017 Jun;103(11):818-826.

Effects of Physical Activity Intervention on Physical and Cognitive Function

in Sedentary Adults With and Without Diabetes. Espeland MA, Lipska K, Miller

ME, Rushing J, Cohen RA, Verghese J, McDermott MM, King AC, Strotmeyer ES,

Blair SN, Pahor M, Reid K, Demons J, Kritchevsky SB; LIFE Study Investigators. J

Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):861-866.

c v i . s ta n fo rd .e d u | 19

Leadership

Joseph C. Wu, MD, PhDDirector, Stanford Cardiovascular Institute Simon H. Stertzer Professor of Medicine and Radiology

Robert A. Harrington, MDArthur L. Bloomfield Professor of Medicine Chair, Dept. of Medicine

Stephen J. Roth, MD, MPHProfessor and Chief, Pediatric CardiologyDirector, Children’s Heart Center

Ronald L. Dalman, MDWalter C. and Elsa R. Chidester Professor of SurgeryChief, Division of Vascular Surgery

Michael Snyder, PhDProfessor and Chair, Dept. of GeneticsDirector, Stanford Center for Genomics and Personalized Medicine

Dominik Fleischmann, MDProfessor, Dept. of RadiologyChief, Cardiovascular Imaging

Y. Joseph Woo, MDNorman E. Shumway Professorin Cardiothoracic SurgeryChair, Dept. of Cardiothoracic Surgery

Kenneth Mahaffey, MDProfessor, Dept. of MedicineVice Chair of Medicinefor Clinical Research

Alan Yeung, MDLi Ka Shing Professor of MedicineCo-Chief (Clinical), Division of Cardiovascular Medicine

Mark Nicolls, MDThe Stanford Professor of Pulmonary and Critical Care Medicine, Dept. of Medicine, Chief, Pulmonary and Critical Care Medicine

Paul Yock, MDMartha Meier Weiland Professor, Bioengineering and Medicine; and Professor, by courtesy, of Mechanical Engineering,Director, Byers Center for Biodesign

Tom Quertermous, MDWilliam G. Irwin Professor of MedicineCo-Chief (Research), Division of Cardiovascular Medicine

Marlene Rabinovitch, MDDwight and Vera Dunlevie Professor in Pediatric Cardiology

c v i . s ta n fo rd .e d u | 20

© STANFORD CARDIOVASCULAR INSTITUTE265 Camus Drive West, G1120

Stanford, CA 94305

cvi.stanford.edu